The Synthesis of a Novel Inhibitor of B-Raf Kinase
摘要:
A scaleable synthetic route to [4,7']bis-isoquinolinyl-1-yl-(2-tert-butyl-pyrimidine-5-yl)amine (1), an inhibitor of B-Raf kinase is described. The key step in the synthesis is the Pd-catalyzed Negishi coupling of 4-bromo-1-chloroisoquinoline with trifluoromethanesulfonic acid isoquinoline-7-yl ester to yield 1-chloro-[4,7']bis-isoquinolinyl. This intermediate is transformed to the desired drug substance in one additional step, by reaction with 2-tert-butyl-5-aminopyrimidine in the presence of NaH. A special focus was put on the finally successful removal of traces of Zn and Pd in the drug substance, which came from the Negishi coupling.
[EN] 1,4-DISUBSTITUTED ISOQUINILONE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DERIVES D'ISOQUINILONE 1,4-DISUBSTITUES EN TANT QU'INHIBITEURS DE RAF-KINASE UTILES POUR LE TRAITEMENT DE MALADIES PROLIFERANTES
申请人:NOVARTIS AG
公开号:WO2005028444A1
公开(公告)日:2005-03-31
This invention relates to compounds of formula (I) wherein the variable substituents are described herein. The compounds are useful for the treatment of conditions and diseases characterized by an aberrant MAP kinase signaling pathway, such as cancer.
1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
申请人:Fink Anne Cynthia
公开号:US20070060582A1
公开(公告)日:2007-03-15
This invention relates to compounds of the formula (I)
wherein the variable substituents are described herein. The compounds are useful for the treatment of conditions and diseases characterized by an aberrant MAP kinase signaling pathway, such as cancer.
Methods for treating proliferative diseases and for monitoring the effectiveness of treatment of proliferative diseases
申请人:Hu Ping
公开号:US20070099250A1
公开(公告)日:2007-05-03
The present invention relates to phosphoproteins useful as biomarkers for identifying and treating patients suffering from diseases characterized by an aberrant MAP kinase signaling pathway, for example proliferative diseases like certain cancers, monitoring the efficacy of treatment of patients having the disease by administering Raf kinase inhibitors and diagnosing the disease in patients.
PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR
申请人:Lane Heidi
公开号:US20090105285A1
公开(公告)日:2009-04-23
A pharmaceutical combination comprising an mTOR inhibitor and a Raf kinase inhibitor and its use.